Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Monoclonal Antibody-Based Targeted Therapy In Breast Cancer

C. Bernard-Marty, F. Lebrun, A. Awada, M. Piccart
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The recent development of monoclonal antibodies targeting growth factor receptors in cancer treatment represents a milestone for both researchers and physicians. Advances in the understanding of key molecular pathways for tumour growth and survival have facilitated the development of these targeted therapies, in particular in breast cancer. This review focuses on the three most important recombinant humanised monoclonal antibodies that have shown activity in women with breast cancer: trastuzumab, pertuzumab and bevacizumab. Trastuzumab, an anti-erbB2 (human epidermal growth factor receptor) monoclonal antibody, is currently routinely used in both the metastatic and adjuvant settings for patients with erbB2-positive tumours. Pertuzumab, a monoclonal antibody binding to a different epitope on erbB2 than trastuzumab, is under early clinical evaluation. This drug has been developed for breast cancer patients, whether overexpressing erbB2 or not. Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor-A, is being evaluated in the metastatic setting for its antiangiogenic properties, and is showing promising results.
This paper references
10.1634/THEONCOLOGIST.7-5-410
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
M. Jahanzeb (2002)
10.1038/sj.onc.1202526
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
M. Pegram (1999)
10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J
Interleukin‐2 enhances the natural killer cell response to Herceptin‐coated Her2 / neu‐positive breast cancer cells
W. Carson (2001)
10.1073/PNAS.96.23.13023
A model-based approach for assessing in vivo combination therapy interactions.
A. López (1999)
10.1023/A:1006159001039
c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
S. de Placido (2004)
Trastuzumab plus [ abstract no . 3 ]
RD Mass (2005)
Trastuzumab and inrodent models
T Repka (2000)
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
A. Petit (1997)
10.1200/JCO.2005.11.030
Proteasome inhibition as a novel therapeutic target in human cancer.
S. Rajkumar (2005)
10.1200/JCO.2005.23.16_SUPPL.868
A multicenter study of trastuzumab (H) and vinorelbine (N) as first and second line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC)
R. Franquesa (2005)
Microvessel density as aHer 2 / neu - positive breast cancer cells
B Uzzan (2001)
10.1128/MCB.20.9.3210-3223.2000
ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency
H. Lane (2000)
10.1016/S0959-8049(03)00673-7
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.
B. Linderholm (2004)
10.1200/JCO.20.3.719
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
A model - based E 279 - 83 approach for assessing in vivo combination therapy interactions
G Gasparini (1999)
pertuzumab (P), a recombinant humanized antibody to HER2
KA Gelmon (2004)
10.1093/ANNONC/MDF076
Fecal occult blood test for colorectal cancer screening.
H. Strul (2002)
10.1200/JCO.2005.05.098
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
K. Miller (2005)
trastuzumab in the therapy of intensively pretreated HER2 overexpressing metastatic breast cancer
C Christodoulou (2000)
Interleukin-2 effects in human rectal cancer
WE Carson (2004)
Twenty - sing metastatic breast cancer : an update including survivalyear results of the Naples GUN randomized trial : predictive [ abstract ]
S DePlacido (2004)
A phase Ib study of progression
KA Gelmon
10.1200/JCO.2001.19.3.851
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
K. Margolin (2001)
10.1093/JNCI/82.1.4
What is the evidence that tumors are angiogenesis dependent?
J. Folkman (1990)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1093/JNCI/DJH131
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
M. Pegram (2004)
10.1146/ANNUREV.PHARMTOX.44.101802.121440
ErbB receptors: directing key signaling networks throughout life.
T. Holbro (2004)
factor-induced angiogenesis suppresses tumour growth
J Bines (1993)
Conditional mutation of the 983252
C Ozcelik
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.
J. Foekens (2001)
10.1038/362841A0
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
K. J. Kim (1993)
10.1200/JCO.2002.20.5.1215
Cardiac dysfunction in the trastuzumab clinical trials experience.
A. Seidman (2002)
HER2-overexpressing metastatic breast cancer: NCCTG study
C Ozcelik (2005)
Trastuzumab and in - rodent models Efficacy and safetystudy
R Gennari
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
Phase II trial of with metastatic breast cancer ( MBC ) with low expression of docetaxel and H / erceptin in metastatic breast cancer patients HER 2 [ abstract no . 3068 ]
MS Gordon (2005)
Insights into ErbB tyrosine kinase and drug - induced DNA repair . Cancer Res signaling from the structure of the ErbB 2 - pertuzumab com - 1994 ; 54 : 3758 - 65 plex
RJ Pietras (2004)
Multicenter Brazilian study of in vivo
J Bines (1993)
10.1016/S1535-6108(02)00097-1
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
D. B. Agus (2002)
10.1053/J.SEMINONCOL.2003.08.006
Dysregulation of cellular signaling by HER2/neu in breast cancer.
B. Zhou (2003)
10.1016/S1359-6349(03)90429-0
397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer
L. Harris (2003)
10.3816/CBC.2003.N.039
Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers.
B. Linderholm (2003)
10.1016/S1359-6349(04)90883-X
Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
S. Takao (2004)
809-20 in treating patients with unresectable locally advanced
HJ Burstein (2006)
Cardiac safety oftrastuzumab in metastatic breast cancer
H Eidtmann (2001)
10.1200/JCO.2004.06.557
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
D. Tripathy (2004)
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
A. Motoyama (2002)
10.1158/1078-0432.CCR-0951-3
Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients
G. Konecny (2004)
10.1038/nature01392
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Hyun-Soo Cho (2003)
10.1159/000076333
A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer
F. Montemurro (2004)
Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin.
P. Borgström (1999)
A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
M. C. Hancock (1991)
10.1002/stem.160413
The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
Jeffrey S. Ross (1998)
10.1093/ANNONC/MDJ110
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.
P. Papaldo (2006)
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
R. Pietras (1994)
Gemcitabine , paclitaxel , and 122
KD Miller
Pharmacokinetics oftive early breast cancer patients : BCIRG 006 study [ abstract HER 2 - targeted rhuMAb 2 C 4 ( pertuzumab ) in patients withno . 1 ]
DE Allison (2005)
In vitro effects of trastuzumab and vi - titumor action of EGFR tyrosine kinase inhibitors . Oncogenenorelbine in trastuzumab - resistant breast cancer cells
MS Neshat (2003)
10.1038/nrc1434
Switching on kinases: oncogenic activation of BRAF and the PDGFR family
Nick J. Dibb (2004)
Docetaxel ( Taxotere ) plus trastuzumab ( Herceptin ) 100
RM Franquesa
Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Makoto Kubo (2003)
10.1158/1078-0432.CCR-04-2569
A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer
M. De Laurentiis (2005)
10.1200/JCO.2004.22.14_SUPPL.728
A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER.
A. Polyzos (2004)
; 9 ( HeCOG )
M Venturini
A multinational phase II cancer : a pilot study
M Untch (2001)
10.1007/s00280-003-0728-3
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
R. Nahta (2003)
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
J. Baselga (1998)
Significantly higher HER-2/neu and vascular endothelial growth factor expression
GE Konecny (2005)
c-erbB 2 expression predicts tamoxifen efficacy in breast cancer patients
S. Placido
10.1038/sj.onc.1206779
Biologic and therapeutic role of HER2 in cancer
S. Ménard (2003)
p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
C. L. Arteaga (1994)
Initial stages of tumor cell - pressing breast cancer
S Shan (2003)
221-30 growth factor in 1307 primary breast cancers
RM Shaheen (2003)
Herceptin) plus docetaxel in patients with metastatic breast
M Untch (2004)
10.1093/JNCI/92.2.143
Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models.
C. Li (2000)
10.1200/JCO.2005.23.16_SUPPL.596
A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results
P. Marcom (2005)
10.1200/JCO.2001.19.18.3808
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
M. Ellis (2001)
Safety and therapy in patients with advanced cancer : pharmacologic andeffectiveness of primary systemic therapy with docetaxel and long - term safety data
K Margolin (2001)
tuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer [abstract no. 969
K Margolin (2003)
10.1200/JCO.2005.23.16_SUPPL.793
Safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer
J. Griggs (2005)
10.1093/ANNONC/MDI901
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology.
M. De Laurentiis (2005)
10.1200/JCO.2004.22.14_SUPPL.636
Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function.
V. Guillem Porta (2004)
10.1053/J.SEMINONCOL.2003.08.013
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.
M. Cobleigh (2003)
10.1016/S1359-6349(04)90846-4
A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)
M. Untch (2004)
10.1126/SCIENCE.1105396
Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors
J. Schlessinger (2004)
Rational signal - regulated kinase or Akt kinase pathways
R Bianco (2003)
756-60 carcinoma cells: association between an oncogenic receptor
MC Franklin (2003)
ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
H. Kurokawa (2003)
[Phase II study].
H. Niitani (1995)
10.1200/JCO.2005.23.16_SUPPL.591
Dose-dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support
M. Jahanzeb (2005)
10.1054/bjoc.2001.1936
Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
R. Shaheen (2001)
10.1038/nm988
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
C. Willett (2004)
A multicenter tients with HER 2 - overexpressing metastatic breast cancer : a phase II study of docetaxel , gemcitabine and trastuzumab phase II trial [ abstract ]
A Polyzos (2002)
Pilot - trial of trastuzumab + erlotinib and pertuzumab against human tumor xenografts is weekly epidoxorubicin / docetaxel in the neoadjuvant treatment superior to monotherapy
T Friess (2005)
Evaluation of clinical outcomes according to HER 2 detection by fluorescence in situ 135
MJ Piccart-Gebhart
; stract ]
HA Burris (2001)
10.3816/CBC.2005.N.026
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
R. Mass (2005)
10.1093/ANNONC/MDJ096
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
B. Coudert (2006)
10.1158/0008-5472.CAN-03-3856
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells
R. Nahta (2004)
10.1158/0008-5472.CAN-03-1957
Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.
B. Uzzan (2004)
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
M. Janmaat (2003)
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
H. Meden (2001)
10.1081/CNV-200032980
Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)
G. Fountzilas (2004)
10.1200/JCO.2004.10.046
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
K. L. Tedesco (2004)
10.1200/JCO.2003.03.124
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
H. Burstein (2003)
10.1200/JCO.2004.22.90140.573
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival
N. J. Robert (2004)
Herceptin ( H ) and taxol pressing human breast cancer xenografts
F Janku (1998)
Long - term survival metastatic breast cancer ( HER 2 + MBC ) [ abstract no . 868 ] . demonstrated with trastuzumab plus docetaxel : 24 - month data
JA O’Shaughnessy (2005)
Trastuzumab and vinorelbine as first - line therapy for HER 2 - overexpressing met - 104
J Nabholtz
anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/Neu overex
L Krasna (1998)
Multicenter phase II
D Yamamoto (2003)
10.1073/PNAS.96.6.3137
Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules.
P. A. Netti (1999)
10.1073/pnas.171076798
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
M. S. Neshat (2001)
10.1016/S0093-7754(01)90191-5
Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
H. Burris (2001)
4 - years results of salts , and trastuzumab in HER 2 - positive advanced breast can - weekly trastuzumab and paclitaxel in the treatment of women cer
AM Lopez (2004)
Efficacy pharmacokinetic study of recombinant human anti - vascular and toxicity of docetaxel or cisplatin chemotherapy in combi - endothelial growth factor in patients with advanced cancer
MA Cobleigh (2001)
630-6 pan East cancer center breast cancer consortium (JECBC
disease. Ann (2004)
Phase II trial of 132 . US National Institutes of Health . TBP study with capecitabine bevacizumab in combination with weekly docetaxel in meta - plus minus trastuzumab [ online ]
KD Miller (2006)
10.1200/JCO.2006.24.18_SUPPL.3050
Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC).
T. Traina (2006)
10.1200/JCO.2005.23.16_SUPPL.802
Multicenter phase II study of trastuzumab (H) and capecitabine (X) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer (Japan Breast Cancer Study Group: JBCSG-003)
D. Yamamoto (2005)
10.1200/JCO.2001.19.10.2587
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
A. Seidman (2001)
10.1016/S0959-8049(01)81187-4
Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene
J. Nabholtz (2001)
p 185 c - erbB2 lular region of HER 2 alone and in complex with the Herceptin signal enhances cisplatin - induced cytotoxicity in human breast Fab
MC Franklin (2003)
Weekly intravenous recom - metastatic breast cancer [ abstract no . 763 ]
H Meden (2004)
Adjuvant 790 ]
H Joensuu (2003)
A meta - analysis bination with paclitaxel or docetaxel for metastatic breaston the interaction between HER - 2 expression and response to cancer [ abstract 182 P ]
Y Sasaki (2002)
10.3816/CBC.2004.N.010
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.
K. Gelmon (2004)
10.3816/CBC.2005.N.047
Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
E. Perez (2005)
10.1158/0008-5472.CAN-03-3106
Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects
J. Jackson (2004)
10.3816/CBC.2003.N.017
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.
G. Fountzilas (2003)
Preoperative therapy static breast cancer that did not respond to previous tras - with trastuzumab and paclitaxel followed by sequential adju - tuzumab [ online ]
HJ Burstein (2003)
A phase I - II 5 : S 141 dose - escalation trial of bevacizumab in previously treated metastatic breast cancer
F Montemurro (2003)
What is the evidence that tumors are angiogenesis of PTEN - deficient tumors to inhibition of FRAP / mTOR . Proc dependent ?
LS Rosen (1990)
py plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2
G Raab (2001)
10.1016/J.EJCA.2004.01.011
Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial.
M. Untch (2004)
10.1200/JCO.2005.23.16_SUPPL.555
Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer
Jean-Marc Extra (2005)
10.1200/JCO.2003.12.109
Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
B. Leyland-Jones (2003)
10.1038/sj.bjc.6602930
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L. Arnould (2006)
10.1038/sj.onc.1206388
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R. Bianco (2003)
10.1038/74704
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
R. Clynes (2000)
Pilot study of the HER 2 - overexpressing metastatic breast cancer
HA Lane (2002)
Dose - dense neoadjuvant ( Herceptin ® ) in treating women with relapsed or metastatic treatment of women with breast cancer utilizing docetaxel , breast cancer [ online ]
M Jahanzeb (2005)
A multicenter in breast cancer
J Extra (2001)
Capecitabine combined 2004 ; 5 ( 2 ) : 1427 with trastuzumab in the therapy of intensively pretreated HER 2 overexpressing metastatic breast cancer
C Christodoulou
10.1200/JCO.2005.23.16_SUPPL.3068
Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2
J. Cortes (2005)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1016/S1359-6349(04)90861-0
Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)
T. Tabei (2004)
10.1056/NEJMOA053028
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
H. Joensuu (2006)
10.1007/s10549-005-9030-x
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
M. Venturini (2005)
10.1038/nrc1360
The discovery of receptor tyrosine kinases: targets for cancer therapy
A. Gschwind (2004)
Inhibition of biologic and therapeutic aspects
B Linderholm (2002)
Response totions of HER - 2 / neu antibody and chemotherapeutic agents epidermal growth factor receptor inhibitors in non - small cellused for treatment of human breast cancers
Pegram (1999)
Phase II study of weekly pertuzumab , a novel erbB dimerization inhibitor , in patients docetaxel and trastuzumab for patients with HER - 2 - overex - with advanced cancer
J Cortes (2005)
10.1158/1078-0432.CCR-04-2642
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
T. Friess (2005)
10.1016/S1535-6108(04)00083-2
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
M. C. Franklin (2004)
10.1200/JCO.2005.23.16_SUPPL.587
Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)
A. Chan (2005)
10.1016/S1359-6349(03)90496-4
464 Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer
B. Bauer-Kosińska (2003)
10.1023/A:1013184301155
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.
G. Fountzilas (2001)
10.1056/NEJMOA052306
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
10.1073/pnas.122249299
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
C. Özcelik (2002)
Use of trastuzumab and docetaxel ( D ) in patients ( pts ) with advanced solid tumors beyond disease progression : observations from a retrospective [ abstract no . 3166 ]
G Fountzilas (2005)
Patients with MBC for patients with HER 2 - positive metastatic breast cancer prospectively selected by FISH derive clinical benefit from ( HER 2 + MBC ) [ abstract no . 243 ]
GH Schwartz (2004)
Phase II trial of breast cancer ( ABC ) overexpressing HER - 2 [ abstract no . 728 ] . weekly vinorelbine and trastuzumab as first - line therapy in
M Jahanzeb (2004)
Importance of VEGF HER 2 - overexpressing stage II or III breast cancer : results of a for breast cancer angiogenesis in vivo : implications from intra - multicenter phase II trial
BP Coudert (2006)
A phase II study of 117 - 24 three - weekly docetaxel and weekly trastuzumab in HER 2 - overexpressing advanced breast cancer
DJ Slamon
Inhibition of vascular endothelial 21 ( 1 ) : 46 - 53 growth factor - induced angiogenesis suppresses tumour growth 139
KJ Kim
10.1200/JCO.2004.22.90140.630
A multi-centre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 over-expressing metastatic breast cancer (MBC)
S. Chia (2004)
10.1038/sj.onc.1202132
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
R. Pietras (1998)
HER-2-targeted therapy: lessons learned and future directions.
R. Nahta (2003)
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
J. Baselga (1999)
10.1016/S0301-472X(99)00089-2
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
S. Cooley (1999)
10.1177/107327480200902S05
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
L. Rosen (2002)
Capecitabine combined
N Bangemann (2004)
Enhancement of fluid
PA Netti (2003)
10.1158/1078-0432.CCR-05-2603
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
B. Ramaswamy (2006)
10.1200/JCO.2005.09.048
Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.
Peter H. Ahn (2005)
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
G. Sledge (2003)
10.1158/1078-0432.CCR-04-0225
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
R. Gennari (2004)
10.3109/9780203092422-17
[Combination treatment].
S. F. Desneibrun (1969)
ErbB (HER) receptors can abrogate three weeks in combination with paclitaxel
H Kurokawa (2003)
; antiestrogen action in human breast cancer by multiple signal - 21 : 3965 - 71 ing mechanisms
G Fountzilas
; dent cellular cytotoxicity mechanism ?
AB Motoyama (2006)
Phase II trial of breast cancer ( Japan Breast Cancer Study Group : JBCSG - 003 ) gemcitabine plus trastuzumab in minimally pretreated HER 2 [ abstract no . 802 ]
HJ Burstein (2005)
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
S. de Placido (2003)
10.1200/JCO.2002.07.058
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
F. Esteva (2002)
10.1200/JCO.2005.03.184
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
D. B. Agus (2005)
10.1053/SONC.2002.34062
Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
G. Sledge (2002)
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
R. Schiff (2003)
Superior outcomes cancer [abstract no. 221
CL Vogel (2003)
Weekly trastuzumab cancer : prognostic factor , predictive factor and target for ther - and paclitaxel therapy for metastatic breast cancer with analy - apy . Stem Cells
JS Ross (1998)
A randomized phase III dermal growth factor receptor 2 - overexpressing breast cancer : trial of paclitaxel versus paclitaxel plus bevacizumab as first - NSABP B31
EH Romond (2005)
HER2-positive metastatic breast cancer [abstract no. 555
JA O’Shaughnessy (2005)
Phase II trial of 132. US National Institutes of Health. TBP study with capecitabine
B Ramaswamy (2003)
Weekly trastuzumab ( Herceptin ) and vinorelbine ( Navelbine ) in chemonaive pa - 105
G Bernardo (2001)
Docetaxel and tras - ticancer Res 1999 ; 19 : 4203 - 14 tuzumab as primary systemic therapy for HER - 2 / neu - overexpressing breast cancer [ abstract no . 969 ]
L Schiffhauer
Phase II study 2005 ; 23 : 17 S of trastuzumab plus gemcitabine in chemotherapy - pretreated patients with metastatic breast cancer
N Bangemann
10.1200/JCO.2001.19.3.843
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
M. Gordon (2001)
10.1200/JCO.2004.22.90140.763
Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer
J. L. Bayo (2004)
4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
F. Janku (2004)
10.3816/CBC.2004.N.019
Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
J. O'Shaughnessy (2004)
10.1200/JCO.2003.02.018
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
H. Burstein (2003)
Recombinant humanized Oncology Group phase II study
J Baselga (2001)
MBC) [abstract no. 443
P Papaldo (2002)
Trastuzumab trial ) [ abstract no . 258 ]
J Bayo (2004)
Paclitaxel results of a phase I trial
C Christodoulou
10.1200/JCO.2005.23.16_SUPPL.3166
A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors
G. Attard (2005)
10.1200/JCO.2005.23.16_SUPPL.704
Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer
N. Peacock (2005)
10.1016/S1359-6349(04)90865-8
Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)
J. Baselga (2004)
10.1200/JCO.2005.23.16_SUPPL.3212
The combination of trastuzumab and vinorelbine as a atractive regimen in overexpressing metastatic breast cancer patients
I. Głogowska (2005)
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
T. Repka (2003)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1093/JNCI/DJH133
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
M. Pegram (2004)
10.1038/416279b
Tumour biology: Herceptin acts as an anti-angiogenic cocktail
Yotaro Izumi (2002)
10.1200/JCO.2005.07.032
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
10.3816/CBC.2004.N.005
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Joshua P Raff (2004)
10.1016/S1535-6108(04)00050-9
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
C. Mitsiades (2004)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
10.1038/NM0195-27
Angiogenesis in cancer, vascular, rheumatoid and other disease
J. Folkman (1995)



This paper is referenced by
10.1371/JOURNAL.PONE.0215442
Conformational characterization of a novel anti-HER2 candidate antibody.
Leina Moro Pérez (2019)
10.1097/CAD.0000000000000095
Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells
Shunchao Yan (2014)
10.1002/cam4.94
Curcumin improves the therapeutic efficacy of Listeriaat-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1
M. Singh (2013)
10.1016/j.breast.2012.09.008
Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
D. Nielsen (2013)
10.1016/j.cjca.2012.08.020
Personalized cardiovascular medicine: status in 2012.
Sonny Dandona (2012)
10.1016/B978-0-12-382030-3.00009-X
Chapter 9 – Prodrugs and Drug Delivery Systems
R. Silverman (2014)
10.1201/B16389-30
Early Markers for Neoplastic Lesions of the Uterine Cervix
P. Conesa-Zamora (2014)
Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy.
K. Hata (2011)
10.1007/s10238-015-0343-8
In vitro antiproliferative effect of trastuzumab (Herceptin®) combined with cetuximab (Erbitux®) in a model of human non-small cell lung cancer expressing EGFR and HER2
G. Privitera (2015)
10.1590/S1516-89132011000100010
In Vivo investigation of radiolabeled Bevacizumab in healthy rat tissues
Ilknur Demir (2011)
10.1016/j.ctrv.2013.01.006
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
P. B. Larsen (2013)
10.1016/bs.ampbs.2016.02.006
Bacterial Electron Transfer Chains Primed by Proteomics.
H. Wessels (2016)
10.1201/B16389-28
Early Biomarkers in Breast Cancer
P. Raina (2014)
10.1007/978-3-0348-0664-0_9
Acquired Resistance to Tamoxifen: Back to the Beginning
P. Maximov (2013)
Community and preventive approach of the mastopathies
E. Caridad (2012)
ASPECTOS CLÍNICO-EPIDEMIOLÓGICOS EN PACIENTES TRATADOS QUIRÚRGICAMENTE POR ENFERMEDAD MAMARIA CLINICAL-EPIDEMIOLOGICAL ASPECTS IN PATIENTS SURGICALLY TREATMENT DUE TO BREAST DISEASE
Yuri López Núñez (2013)
Evaluation of wild type and mutants of β-Glucuronidase (GUS) against natural and synthetic substrates
S. Tiwari (2014)
10.1200/JCO.2009.25.5414
Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials.
E. D. Saad (2010)
Semantic Scholar Logo Some data provided by SemanticScholar